Company overview
Cytosurge is a synthetic biology company specializing in precision gene-engineered mammalian cell line manufacturing using patented FluidFM technology. The company enables vector-free, single-cell genome editing with applications in CRISPR gene editing, cell and gene therapy production, and biopharmaceutical manufacturing. Cytosurge bridges the gap between genetic design tools and tangible production of complex engineered cell lines for next-generation therapeutics.
Go beyond in single-cell manipulation is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include gene editing, cell line engineering, crispr technology, single-cell manipulation, synthetic biology.
Structured facts
- Website
- https://www.cytosurge.com
- Markets served
- United States & Americas
- Keywords
- gene editing, cell line engineering, crispr technology, single-cell manipulation, synthetic biology
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is Cytosurge's core technology platform?
- Cytosurge's proprietary FluidFM technology combines microfluidics and force microscopy through closed microscopic channels in force-sensitive probes. This enables non-destructive single-cell access, perturbation, and analysis of the same living cell over time, supporting applications in gene editing, single-cell profiling, and biopsying.
- What gene editing services does Cytosurge offer?
- Cytosurge's CellEDIT service delivers vector-free, stoichiometrically controlled knockouts, knockins, and multiplex genome edits using direct intra-nuclear injection. The platform is effective even in hard-to-transfect cells and minimizes CRISPR-related toxicity through precise single-cell targeting.
- What are the primary applications for pharmaceutical and biotech companies?
- Key applications include engineering cell lines for pharmaceutical production, cell and gene therapy manufacturing, CRISPR-based multiplexed gene editing, and development of transplantable organs. The FluidFM OMNIUM platform also enables live-cell sequencing and temporal RNA analysis for cellular characterization.
- Does Cytosurge support regulatory-grade cell line development?
- Cytosurge specializes in manufacturing advanced gene-engineered mammalian cell lines with precision control and dynamic gene expression analytics. The company's single-cell bottom-up approach enables construction, evaluation, and debugging of complex synthetic cell lines suitable for biopharmaceutical applications.
- What partnerships has Cytosurge established?
- Cytosurge collaborates with Harvard's Wyss Institute on CRISPR multiplexing research and partners with Lexogen to integrate FluidFM technology with live-cell sequencing workflows, combining cell biopsying with RNA analysis capabilities.
Related editorial coverage
- Eli Lilly and Verve's Gene Editor: A Breakthrough in Cholesterol Management
- ASGCT 2026: Manufacturing Innovations Day 1 Roundup
- Intellia Therapeutics Achieves First-Ever Positive Phase 3 Results for In Vivo Gene Editing with Lonvoguran Ziclumeran in Hereditary Angioedema
Explore lab tools and QA/QC resources for R&D teams.
